Company intelligence / Profile preview

Ona Therapeutics

Barcelona, Catalonia, Spainona-therapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Ona Therapeutics is advancing a pipeline of first-in-class antibody-drug conjugates and monoclonal antibodies targeting advanced solid tumors. Lead program ONA-255 is in IND-enabling studies for breast and other solid tumors, with clinical trials expected to begin by the end of 2025. Additional programs include ONA-389 ADC for prevalent solid tumors and ONA-036 mAb targeting CD36. No clinical results have been reported as all programs are preclinical or IND-enabling.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibodyBiologic
Industry: Biotech

Drug pipeline

4 assets

ONA-255

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Biocytogen Pharmaceuticals

Beyond the preview

Go deeper on Ona Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ona Therapeutics.

Explore the full profile